<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Endoscopic mucosal ablation is a promising technique that is used to treat dysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study was to investigate the efficacy and cost-effectiveness of two promising techniques, <z:chebi fb="17" ids="49474,49475">argon</z:chebi> plasma coagulation (APC) and photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>), in the ablation of dysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: Twenty-six patients with dysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (21 M, median age 60 years, median length 4 cm, 23 low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (LGD), 3 high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD)) were randomized to APC: 13 patients, <z:chebi fb="7" ids="53228">PDT</z:chebi>: 13 patients </plain></SENT>
<SENT sid="3" pm="."><plain>APC was performed at a power setting of 65 W and <z:chebi fb="17" ids="49474,49475">argon</z:chebi> gas flow at 1.8 l/min in 1-6 sessions (mean 5) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="7" ids="53228">PDT</z:chebi> was performed 48 h after intravenous injection of Photofrin 2 mg/kg with a 630 nm red laser light, 200 J/cm through a <z:chebi fb="7" ids="53228">PDT</z:chebi> balloon in one session </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received treatment with high-dose <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Cost analysis was undertaken and the results were assessed by endoscopy and biopsies at 4 months and 12 months after therapy </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients in both groups showed a reduction in the length of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The median length of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> eradicated at the 4-month follow-up: APC 65%, <z:chebi fb="7" ids="53228">PDT</z:chebi> 57% and at the 12-month follow-up: APC 56%, <z:chebi fb="7" ids="53228">PDT</z:chebi> 60% </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_589'>Dysplasia</z:mpath> eradication at 4 months: APC 62%, <z:chebi fb="7" ids="53228">PDT</z:chebi> 77%, p = 0.03 (95% CI 0.66-0.96) and at 12 months APC 67%, <z:chebi fb="7" ids="53228">PDT</z:chebi> 77% </plain></SENT>
<SENT sid="10" pm="."><plain>Buried columnar glands with <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> were seen in both groups, with one patient in the <z:chebi fb="7" ids="53228">PDT</z:chebi> arm developing adenocarcioma under the neo-squamous epithelium </plain></SENT>
<SENT sid="11" pm="."><plain>Severe adverse events included APC 2/13 (15%) stricture, 1/13 (8%) odynophagia, <z:hpo ids='HP_0100749'>chest pain</z:hpo> and <z:hpo ids='HP_0001945'>fever</z:hpo>; <z:chebi fb="7" ids="53228">PDT</z:chebi> 2/13 (15%) <z:hpo ids='HP_0000992'>photosensitivity</z:hpo>, 2/13 (15%) stricture </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="7" ids="53228">PDT</z:chebi> would cost an additional 266 pounds sterling for every percentage reduction in Barrett's length and 146 pounds sterling per percentage reduction in <z:mpath ids='MPATH_589'>dysplasia</z:mpath> compared with APC treatment </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: APC and <z:chebi fb="7" ids="53228">PDT</z:chebi> are equally effective in eradicating Barrett's mucosa, with <z:chebi fb="7" ids="53228">PDT</z:chebi> being the more expensive treatment </plain></SENT>
<SENT sid="14" pm="."><plain>However, <z:chebi fb="7" ids="53228">PDT</z:chebi> is more effective in eradicating <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and the extra benefits of <z:chebi fb="7" ids="53228">PDT</z:chebi> are generated at an extra cost </plain></SENT>
<SENT sid="15" pm="."><plain>The occurrence of buried columnar glands and <z:mp ids='MP_0002038'>carcinoma</z:mp> warrants caution </plain></SENT>
<SENT sid="16" pm="."><plain>Long-term follow-up is needed to assess <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevention and the durability of the neo-squamous epithelium to justify these interventions </plain></SENT>
</text></document>